Artiva Biotherapeutics, Inc. (ARTV) Income Statement
ARTV 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsARTV revenue and net income
ARTV profit margins
ARTV growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −1,134.7% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ARTV quarterly EPS vs estimates
Artiva Biotherapeutics beat the analyst EPS estimate in 1 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.54).
ARTV income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $251,000 | $33.5M | $4.9M | $2.0M | $0 |
| Cost of revenue | $2.6M | $0 | $0 | $0 | $0 | — |
| Gross profit | −$2.6M | $251,000 | $33.5M | $4.9M | $2.0M | — |
| Research & development | $69.5M | $50.3M | $50.3M | $44.0M | $42.4M | $13.8M |
| Sales, general & admin | $20.3M | $17.2M | $13.9M | $20.8M | $12.9M | $4.4M |
| Total operating expenses | $88.0M | $67.5M | $64.2M | $64.8M | $55.3M | $18.3M |
| Operating income | −$90.6M | −$67.3M | −$30.7M | −$59.8M | −$53.3M | −$18.3M |
| Interest income | $6.0M | $5.3M | $2.5M | $1.3M | $0 | $2,000 |
| Interest expense | — | — | — | — | $0 | $199,000 |
| Income before taxes | −$83.9M | −$58.5M | −$27.6M | −$58.3M | −$71.8M | −$18.0M |
| Income taxes | — | — | $72,000 | $53,000 | −$18.6M | $676,000 |
| Net income | −$83.9M | −$58.5M | −$27.7M | −$58.4M | −$71.8M | −$18.0M |
| EBITDA | −$81.3M | −$56.1M | −$25.4M | −$57.2M | −$71.6M | −$17.5M |
| EPS (diluted) | −$3.42 | −$25.02 | −$1.36 | — | — | — |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating margin | — | −26,805.6% | −91.6% | −1,213.3% | −2,660.9% | — |
| Net margin | — | −23,304.0% | −82.7% | −1,184.1% | −3,587.7% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $251,000 | $2.4M | $26.7M |
| Cost of revenue | — | $666,000 | $666,000 | $662,000 | — | — | — | — | — | $0 | $0 | $0 |
| Gross profit | — | −$666,000 | −$666,000 | −$662,000 | — | — | — | — | — | $251,000 | $2.4M | $26.7M |
| Research & development | $21.9M | $19.3M | $17.0M | $17.6M | $17.9M | $17.1M | $13.3M | $13.5M | $12.3M | $11.2M | $11.2M | $13.1M |
| Sales, general & admin | $5.0M | $5.1M | $4.9M | $5.3M | $4.9M | $5.1M | $5.0M | $4.8M | $3.9M | $3.6M | $3.2M | $2.8M |
| Total operating expenses | $26.9M | $23.8M | $21.9M | $22.9M | $22.8M | $22.2M | $18.3M | $18.3M | $16.2M | $14.7M | $14.3M | $15.8M |
| Operating income | −$26.9M | −$24.4M | −$21.9M | −$22.9M | −$22.8M | −$22.2M | −$18.3M | −$18.3M | −$16.2M | −$14.5M | −$12.0M | $10.8M |
| Interest income | $1.9M | $912,000 | $1.2M | $1.4M | $1.6M | $1.9M | $2.2M | $1.8M | $676,000 | $650,000 | $583,000 | $418,000 |
| Income before taxes | −$25.0M | −$23.5M | −$20.8M | −$21.5M | −$21.3M | −$20.3M | −$9.2M | −$17.5M | −$17.8M | −$14.0M | −$11.9M | $11.3M |
| Income taxes | — | — | — | — | — | — | — | — | −$1.7M | −$382,000 | $72,000 | — |
| Net income | −$25.0M | −$23.5M | −$20.8M | −$21.5M | −$21.3M | −$20.3M | −$9.2M | −$17.5M | −$17.8M | −$14.0M | −$12.0M | $11.3M |
| EBITDA | −$23.6M | −$22.9M | −$20.1M | −$20.9M | −$20.6M | −$19.7M | −$8.6M | −$16.8M | −$17.2M | −$13.4M | −$11.3M | $11.8M |
| EPS (diluted) | −$0.63 | −$0.95 | −$0.84 | −$0.88 | −$0.87 | −$0.83 | −$0.66 | −$0.87 | −$22.00 | −$1.49 | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating margin | — | — | — | — | — | — | — | — | — | −5,773.7% | −509.4% | 40.6% |
| Net margin | — | — | — | — | — | — | — | — | — | −5,562.9% | −510.6% | 42.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ARTV's financial statements (latest annual report filed March 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ARTV financial results
Artiva Biotherapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $83.9 million. Diluted earnings per share came to −$3.42.
See the ARTV stock overview for the latest quote and news, or the ARTV chart for price history and technical indicators.
ARTV income statement FAQ
Does Artiva Biotherapeutics have revenue?
Artiva Biotherapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Artiva Biotherapeutics profitable?
No. Artiva Biotherapeutics reported a net loss of $83.9 million in fiscal 2025.
How much does Artiva Biotherapeutics spend on research and development?
Artiva Biotherapeutics spent $69.5 million on research and development in fiscal 2025.
What are Artiva Biotherapeutics's earnings per share?
Artiva Biotherapeutics earned $-3.42 per diluted share in fiscal 2025, compared with $-25.02 a year earlier.
When will Artiva Biotherapeutics report its next earnings?
Artiva Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Artiva Biotherapeutics's fiscal year end?
Artiva Biotherapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 10, 2026.